Myriad Matters Blog

Six years ago, my doctor told me I had prostate cancer, and the news literally brought me to my knees. To…

On August 13, 2015, Medicare approved coverage of the Prolaris® test for men diagnosed with low-risk and very low-risk prostate cancer.…

Myriad has led the industry in genetic testing for hereditary breast and ovarian cancer since the launch of BRACAnalysis® in 1996.…

All of us at Myriad – from the executives and researchers, to the sales and customer service representatives – work hard…

Data recently presented by Myriad Genetics’ prostate cancer prognostic test Prolaris is getting healthcare professionals and patients interested in learning more…

SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal…

This past week Myriad Genetic Laboratories had the opportunity to present 2 posters at the Society for Urologic Oncologists that was…

SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled “CCP Score Significantly Predicts PSA…

The Great Prostate Cancer Challenge (GPCC) is the premier men’s health race and event series in America.  It is an exciting…

This BRCA2 positive patient has had a mastectomy and prostatectomy. Yes, you read that correctly. Meet Robert, a male HBOC carrier…